301 related articles for article (PubMed ID: 27207870)
1. Multiple sclerosis disease-modifying therapy and pregnancy.
Miller AE
Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
[No Abstract] [Full Text] [Related]
2. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
3. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M; Palace J
Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
[No Abstract] [Full Text] [Related]
4. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger J; Freedman M
Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
[No Abstract] [Full Text] [Related]
5. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
6. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta and glatiramer acetate therapy.
McGraw CA; Lublin FD
Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
[TBL] [Abstract][Full Text] [Related]
8. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
Rotondi M; Bergamaschi R; Chiovato L
Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
Garattini L; Ghislandi F; Da Costa MR
Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
[No Abstract] [Full Text] [Related]
10. Multiple Sclerosis.
Reich DS; Lucchinetti CF; Calabresi PA
N Engl J Med; 2018 Jan; 378(2):169-180. PubMed ID: 29320652
[No Abstract] [Full Text] [Related]
11. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
12. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
13. Multiple sclerosis: monotherapy rules.
Hauser SL; Josephson SA; Johnston SC
Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Tsareva E; Kulakova O; Boyko A; Favorova O
Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
[TBL] [Abstract][Full Text] [Related]
15. Concomitant therapy for multiple sclerosis.
Stuart WH; Vermersch P
Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
[TBL] [Abstract][Full Text] [Related]
16. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
[TBL] [Abstract][Full Text] [Related]
17. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.
Lu E; Wang BW; Guimond C; Synnes A; Sadovnick D; Tremlett H
Neurology; 2012 Sep; 79(11):1130-5. PubMed ID: 22933738
[TBL] [Abstract][Full Text] [Related]
19. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.
Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H
Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]